Updates in the management of polycythemia vera and essential thrombocythemia by Prithviraj Bose, Srdan Verstovsek

Get full text

MF management by Prithviraj Bose, Srdan Verstovsek

Get full text

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives by Prithviraj Bose, Srdan Verstovsek

Get full text

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy by Sophia S. Lee, Srdan Verstovsek, Naveen Pemmaraju

Get full text

Momelotinib: an emerging treatment for myelofibrosis patients with anemia by Helen T. Chifotides, Prithviraj Bose, Srdan Verstovsek

Get full text

How we diagnose and treat WHO-defined systemic mastocytosis in adults by Ayalew Tefferi, Srdan Verstovsek, Animesh Pardanani

Get full text

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA by Melisa Palacio, Srdan Verstovsek, Tomonori Uno, Taishi Yamashita

Get full text

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety by Srdan Verstovsek, Ruben A. Mesa, Robert A. Livingston, Wilson Hu, John Mascarenhas

Get full text

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis by Ivo Veletic, Sanja Prijic, Taghi Manshouri, Graciela M. Nogueras-Gonzalez, Srdan Verstovsek, Zeev Estrov

Get full text

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies by Srdan Verstovsek, Olatoyosi Odenike, Jack W. Singer, Tanya Granston, Suliman Al-Fayoumi, H. Joachim Deeg

Get full text

Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis by Alanna Barrios-Ruiz, Daniel Davila-Gonzalez, Eric Fountain, Lee Cheng, Srdan Verstovsek, Cristhiam M. Rojas-Hernandez

Get full text

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes by Taghi Manshouri, Ivo Veletic, Ping Li, C. Cameron Yin, Sean M. Post, Srdan Verstovsek, Zeev Estrov

Get full text

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies by Abdallah Abou Zahr, Mohamed E. Salama, Nicole Carreau, Douglas Tremblay, Srdan Verstovsek, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Get full text

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis by Hans Michael Kvasnicka, Jürgen Thiele, Carlos E. Bueso-Ramos, William Sun, Jorge Cortes, Hagop M. Kantarjian, Srdan Verstovsek

Get full text

Therapy-related myelofibrosis does not appear to exist by Lucia Masarova, Gabriele Todisco, Taghi Manshouri, Kate J. Newberry, Jorge E. Cortes, Hagop M. Kantarjian, Zeev Estrov, Srdan Verstovsek

Get full text

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy by Alfonso Quintás-Cardama, Hagop Kantarjian, Susan O’Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, Srdan Verstovsek, Jianqin Shan, Jorge Cortes

Get full text

P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS by Andrew Kuykendall, Marina Kremyanskaya, Yelena Ginzburg, Naveen Pemmaraju, Abdulraheem Yacoub, Frank Valone, Sarita Khanna, Suneel Gupta, Srdan Verstovsek, Ronald Hoffman

Get full text

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN) by Lucia Masarova, Srdan Verstovsek, Tom Liu, Sumati Rao, Guatam Sajeev, Ryan Simpson, Weilong LI, Joseph Yang, Boris Gorsh, James Signorovitch

Get full text

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis by Jason Gotlib, John H. Baird, Tracy I. George, Cheryl Langford, Isabel Reyes, Justin Abuel, Cecelia Perkins, Kurt Schroeder, Prithviraj Bose, Srdan Verstovsek

Get full text

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy by Naveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, Elias Jabbour, Alfonso Quintas-Cardama, Srdan Verstovsek, Farhad Ravandi, William Wierda, Susan O’Brien, Jorge Cortes

Get full text